Zoledronic Acid is Superior to TDF-Switching for Increasing Bone Mineral Density in HIV-Infected Adults with Osteopenia: A Randomised Trial

Hoy J1,2, Richardson R3, Ebeling PR2, Rohas J4, Pocock N5, Kerr S6, Martinez E4, Carr A6; ZEST (Zoledronic acid or Switch Tenofovir) study investigators

1 The Alfred Hospital, Melbourne, Australia, 2Monash University, Melbourne, Australia, 3St Vincent’s Hospital, Centre for Applied Medical Research, Sydney, Australia, 4Hospital Clinic, University of Barcelona, Infectious Diseases Unit, Barcelona, Spain, 5St Vincent’s Hospital, Sydney, Nuclear Medicine, Sydney, Australia, 6St Vincent’s Hospital, Sydney, HIV, Immunology and Infectious Diseases Unit, Sydney, Australia

Background: Tenofovir disoproxil fumarate (TDF) reduces bone mineral density (BMD) and probably increases fracture risk in HIV-infected adults. Proven strategies for improving BMD in HIV-infected adults on TDF are either TDF switching or bisphosphonate therapy; which strategy is superior is unknown.

Methods: We randomised virologically-suppressed, HIV-infected adults on TDF-based antiretroviral therapy with low BMD (T score < -1.0 at hip or spine by dual-energy x-ray absorptiometry [DXA]) to either switch TDF or to continue TDF and receive intravenous zoledronic acid (ZOL) 5mg every 12 months. Calcium (all patients) and vitamin D (if serum 25OH vitamin D was <50 nmol/L) were supplemented. The primary study outcome was change in lumbar (L1-L4) spine BMD at 24 months by intention-to-treat analysis. Secondary outcomes included femoral neck and total hip BMD, fractures, safety, and virological failure (confirmed viral load ≥400 copies/mL).

Results: We randomised 87 patients (44 to TDF switch and 43 to ZOL): mean age 50 years (SD 11), 96% men, mean TDF duration 5.9 years (SD 3.1), 22% on a boosted PI, mean spine and hip T scores -1.6 and -1.3, respectively. TDF switches were mostly to abacavir (62%) or raltegravir (19%). Adherence to each strategy was high: four switch patients (10%) recommended TDF at a median of 9 months; 98% of ZOL doses were administered. Mean spine BMD changes at 24 months were 7.4% (SD 4.3%) with ZOL vs. 2.9% (4.5%) with TDF-switching (mean difference 4.4%, 95%CI 2.6-6.3; p<0.001). Mean left femoral neck BMD changes were 4.1% (3.8%) and 2.1% (4.6%), respectively (mean difference 2.0%, 95%CI 0.2-3.8; p=0.03). Mean left total hip BMD changes were 4.6% (2.6%) and 2.6% (4.0%), respectively (mean difference 1.9%, 95%CI 0.5-3.4; p=0.009). There was 1 fracture in the ZOL group (1 patient) and 7 separate fracture events in the TDF switch group (4 patients). Serious adverse events occurred in 9 (19%) ZOL patients and 6 (14%) TDF-switch patients; none was related to study drugs or procedures. Virological failure occurred in 1 TDF-switch patient and no ZOL patient.

Conclusions: ZOL is more effective than TDF switching at increasing BMD in osteopenic adults on TDF, and may result in fewer fractures.
Disclosure of Interest Statement: This study was funded by an NHMRC grant APP1022660. Jennifer Hoy’s institution has received reimbursement for her participation in Advisory Boards for Gilead Sciences, ViiV Healthcare and AbbVie.